The Infect of Olmesartan on Atrial Fibrillation Load in Patients with Sick Sinus Syndrome

The Infect of Angiotensin receptor antagonist on Atrial Remodeling Load in Patients with Sick Sinus Syndrome

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12004443

Enrollment

Unknown

Registered

2012-01-16

Start date

2013-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sick Sinus Syndrome

Interventions

the treatment group:Valsartan

control group:Placebo

Eligibility

Sex/Gender

All

Age

35 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) the patients implanted dural-chamber pacemaker bacause of Sick Sinus Syndrome, having the record of atrial fibrillation load and high frequency atrial incident from Janurary 2010 to December 2011; (2) having the clear history of paroxymal atrial fibrillation (proving by ECG or Holter).

Exclusion criteria

Exclusion criteria: (1) LAD>>60mm; (2) Cardiac function NYHA III or IV; (3) High potassium (>5.5mmol/l); (4) Using Anti-arrhythmic drugs (I-IV class); (5) Severe kidney, liver, lungs and other diseases.

Design outcomes

Primary

Measure	Time frame
AF load;	—

Secondary

Measure	Time frame
LAD;LAEF;aldosterone;Potassium;	—

Countries

China

Contacts

Public ContactHang Zhang

Nanjing First Hospital Department Of Cardiology

dxh_nari@sina.com+86 13951922158

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 1, 2026